Adjuvant Therapy for Urothelial and Renal Cell Carcinoma

Hiten D. Patel*, Max Kates, Mohamad E. Allaf

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

6 Scopus citations


Adjuvant therapy for urothelial and renal cell carcinoma has progressed steadily over the past 30 yr. Level 1 evidence supports a role for both neoadjuvant and adjuvant cisplatin-based chemotherapy for muscle-invasive urothelial carcinoma of the bladder. Recent evidence has also confirmed a benefit from adjuvant therapy in high-grade upper tract urothelial carcinoma. Adjuvant targeted therapy remains controversial and outside the standard of care for renal cell carcinoma, with no proven overall survival benefit. Immune checkpoint blockade is poised to shift the landscape for both urothelial and renal cell carcinoma with the potential for greater efficacy.

Original languageEnglish (US)
Pages (from-to)3-6
Number of pages4
JournalEuropean Urology Focus
Issue number1
StatePublished - Jan 15 2020

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Adjuvant Therapy for Urothelial and Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this